PharmaShots | Incisive News in 3 Shots

Subscribe Now

Six-Week

Merck & Co. Reports the Resubmission of sBLA to the US FDA for Keytruda (pembrolizumab) Six-Week Dosing Schedule

Merck & Co. Reports the Resubmission of sBLA to the US FDA for Keytruda (pembrolizumab) Six-Week Dosing Schedule

April 24, 2020

Merck Reports FDA's Acceptance of sBLA of Keytruda (pembrolizumab) with Six-Week Dosing Schedule for Multiple Indications

Merck Reports FDA's Acceptance of sBLA of Keytruda (pembrolizumab) with Six-Week Dosing Schedule for Multiple Indications

July 9, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us